CYP2B6 GENOTYPE BASED EFAVIRENZ DOSE RECOMMENDATIONS DURING RIFAMPICIN-BASED ANTITUBERCULOSIS CO-TREATMENT FOR A SUB-SAHARAN AFRICA POPULATION | BMJ Global Health

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Blog

Supplements
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

XML

ABSTRACTS OF THE EIGHTH EDCTP FORUM, 6–9 NOVEMBER 2016

ABSTRACTS OF POSTER PRESENTATIONS

PA-069

CYP2B6 GENOTYPE BASED EFAVIRENZ DOSE RECOMMENDATIONS DURING RIFAMPICIN-BASED ANTITUBERCULOSIS CO-TREATMENT FOR A SUB-SAHARAN AFRICA POPULATION

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Mukonzo J, Kuteesa R, Ogwal-Okeng J, et al

CYP2B6 GENOTYPE BASED EFAVIRENZ DOSE RECOMMENDATIONS DURING RIFAMPICIN-BASED ANTITUBERCULOSIS CO-TREATMENT FOR A SUB-SAHARAN AFRICA POPULATION

BMJ Global Health 2017;2:A39.